Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial"

被引：0

作者：

Mordi, Ify R. ^{[1
]}

Mohan, Mohapradeep ^{[1
]}

Lang, Chim C. ^{[1
]}

机构：

[1] Univ Dundee, Div Mol & Clin Med, Dundee, Scotland

来源：

CIRCULATION | 2020年 / 141卷 / 04期

关键词：

D O I：

10.1161/CIRCULATIONAHA.119.043268

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E55 / E56

页数：2

共 44 条

[21] Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial
Ferreira, Joao Pedro
Neves, Joao Sergio
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (11)
[22] Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'
Branch, Kelley R. H.
Gerstein, Hertzel C.
Probstfield, Jeffrey L.
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (11) : 2207 - 2208
[23] Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"
Xie, Jian
Jiang, Mingyang
Li, Lang
CIRCULATION, 2019, 139 (22) : E1015 - E1016
[24] Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus"
Musso, Giovanni
Cassader, Maurizio
Gambino, Roberto
CIRCULATION, 2017, 136 (16) : 1563 - 1564
[25] Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)"
Figtree, Gemma A.
Radholm, Karin
Neal, Bruce
CIRCULATION, 2019, 139 (03) : 418 - 419
[26] Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease"
Wanner, Christoph
von Eynatten, Maximilian
Zinman, Bernard
CIRCULATION, 2018, 138 (08) : 850 - 851
[27] Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)"
Donzelli, Alberto
Schivalocchi, Alessandro
Giudicatti, Giulia
CIRCULATION, 2018, 138 (17) : 1912 - 1913
[28] Letter by Morgan et al Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial"
Morgan, Holly
Clayton, Tim
Perera, Divaka
CIRCULATION, 2021, 143 (20) : e959 - e960
[29] Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial"
Mann, Johannes F. E.
Fonseca, Vivian
Mosenzon, Ofri
Raz, Itamar
Goldman, Bryan
Idorn, Thomas
von Scholten, Bernt Johan
Poulter, Neil R.
CIRCULATION, 2019, 139 (22) : E1017 - E1018
[30] Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial"
Lopes, Renato D.
Alexander, Karen P.
Hochman, Judith S.
Maron, David J.
CIRCULATION, 2021, 143 (20) : e961 - e962

← 1 2 3 4 5 →